Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting ...

Retrieved on: 2023-01-04 05:02:04

Tags for this article:

Medicine

Medical specialties

Clinical medicine

Immunology

RTT

Monoclonal antibodies

Antineoplastic drugs

Immune system

Prostate cancer

Monoclonal antibody therapy

Transcenta Holding Limited

Click the tags to see associated articles and topics

Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting .... View article details on HISWAI: https://www.prnewswire.com/news-releases/transcenta-received-ind-clearance-from-nmpa-for-its-first-in-class-gremlin1-targeting-antibody-tst003-for-the-treatment-of-solid-tumors-301712331.html

Excerpt

Gremlin1-specific antibodies can effectively control tumor growth in ... TST003 is a high affinity monoclonal antibody targeting Gremlin1, ...

Article found on: www.prnewswire.com

View Original Article